Paula Rodríguez Otero, MD, PhD, on Demonstrating Ide-cel's PFS Superiority in Triple-Class-Exposed R/R Multiple Myeloma

Commentary
Video

The hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.

“After a median follow up of 31 months, ide-cel continued to show significantly longer and clinically meaningful improvement in progression-free survival versus the standard regimens...”

Idecabtagene vicleucel (ide-cel; Bristol Myers Squibb, 2seventybio) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy marketed under the name Abecma. It is currently FDA-approved for the treatment of patients with relapsed/refractory (r/r) multiple myeloma (MM) after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.1 Although, it is currently under clinical evaluation as a potential option for earlier lines of treatment. The ongoing phase 3 KarMMa-3 clinical trial (NCT03651128) is currently evaluating the cell therapy against standard of care (SOC) combination regimens for patients with early-line (2 to 4 prior lines) triple-class-exposed r/r MM.2

An updated analysis of progression-free survival (PFS) data from KarMMa-3 was recently presented by Paula Rodríguez Otero, MD, PhD, a hematologist at the University of Navarra, at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California. The new data, which was the final analysis of PFS for the trial, demonstrated ide-cel's superiority over SOC regimens in terms of PFS for the population of treated patients.

Shortly after the close of the conference, CGTLive™ sat down with Otero to learn more about the analysis she presented. Otero gave an overview of the key data presented, noting that in addition to the PFS results she also presented interim data for overall survival, which was a secondary end point in KarMMa-3. She pointed out that although the study was not powered to give definitive results for OS and that the data was confounded by patient crossover from SOC to ide-cel use, a planned sensitivity analysis adjusting for crossover favored ide-cel over SOC for OS. Otero also touched on ide-cel's safety profile in KarMMa-3 and the importance of effective bridging therapy in CAR-T studies of this type.

Click here for more coverage of ASH 2023.

REFERENCES
1. U.S. Food and Drug Administration approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. News release. Bristol Myers Squibb and bluebird bio. March 26, 2021. Accessed December 14, 2023. https://bwnews.pr/39jWjjd
2. Otero PR, Ailawadhi S, Arnulf B, et al.Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): updated analysis from KarMMa-3. Presented at: ASH 2023 Annual Meeting & Exposition. December 9-12; San Diego, CA. Abstract #1028

Related Videos
Pat Furlong, BSN, RN
N. Nora Bennani, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
David Porter, MD
Heather Lau, MD, MS, the executive director of global clinical development at Ultragenyx Pharmaceutical
Peter A. Merkel, MD, MPH, the chief of the Division of Rheumatology and a professor of medicine and professor of epidemiology at Penn Medicine
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Julie Kanter, MD
Salvador Rico, MD, PhD
Marcela Maus, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.